(INNE)
ZANIDATAMAB ZOVODOTINE(INNF)
ZANIDATAMAB ZOVODOTINA(INNS)
ZANIDATAMAB ZOVODOTIN(INND)
ZANIDATAMAB ZOVODOTIN(CZ)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-[HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINE PROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)], HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPPING EPITOPES ON ERBB2, ON EXTRACELLULAR DOMAINS 2 (ECD2) AND 4 (ECD4)), CONJUGATED TO A DERIVATIVE OF AURISTATIN; CORRECTED PROPOSED INN: LIST 126(WHO)
ZANIDATAMABUM ZOVODOTINUM(INN)